XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
M

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burden With Ropeginterferon Alfa-2b vs. SoC? Is 2L Ruxolitinib the Best Choice for HU-Resistant Patients?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
0 views
January 18, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
MDS and MPN
21:56
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Leukemic Transformations of MPNs: What Mutations Are Associated With…

Feat. T. Mughal
25:23
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Essentials: How Common Are Comorbidities? Should Risk Score Dete…

Feat. M. Çetiner
09:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

LR-MDS: Are ESAs Effective in the Treatment of Anemia? Is PLT Transf…

Feat. M. Mittelman
10:25
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

HR-MDS: Are HMAs the Best Option? Should We Consider Changing the Pa…

Feat. M. Mittelman
22:45
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burd…

Feat. M. Ellis
12:47
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Updates: Can We Achieve Long-Term Transfusion Independence With …

Feat. G. Garcia-Manero